Akebia Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript
Good morning, everyone. Welcome to the 2020 Jefferies Healthcare Conference. I am Michael Yee, a managing director at Jefferies on the biotech team. Kicking us off this morning I am very happy to have the CEO of Akebia Therapeutics, John Butler, on with us.
Obviously John recently announced some very positive data for his new drug, Vadadustat. And without further ado I will turn it over to John who will give you an update on the story and all of the plans for Akebia. So, John, take it away.
Mike thanks so much, really appreciate the opportunity to come and speak to you today about Akebia. Just reminding everyone that we're going to be making forward-looking statements today, so please refer to our SEC filings for more information.
It really is an incredibly exciting time at Akebia right now. Akebia is a fully integrated biopharma company focused on delivering therapeutic options to better the life of each person impacted by kidney disease.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
